Canaccord Genuity Appoints Dr. Julian Feneley

Canaccord Financial Inc - Canaccord Genuity Appoints Dr. Julian Feneley

PR Newswire

London, March 19

LONDON, 19 March 2013 -Canaccord Genuity is pleased to announce that Dr. JulianFeneley will be joining the company as Head of Healthcare Investment Banking,Europe. Julian has over 20 years of healthcare industry experience as aninvestment banker and as a CEO. He will lead Canaccord Genuity's coverage ofthe European Healthcare sector from London and will report to Adrian Haxby,Head of European Investment Banking.

"We are very pleased to welcome Julian's deep Healthcare expertise andexperience to our growing Healthcare team. He will play a key role in furtherstrengthening our advisory capabilities in this important sector," statedAlexis de Rosnay, CEO of Canaccord Genuity Limited.

Prior to accepting the role at Canaccord Genuity, Julian held leadershippositions at public and private companies and investment banks. At JP Morgan,where he was a senior member of their Healthcare investment banking franchisein Europe, he advised on a number of pivotal cross-border transactionsincluding the creation of Novartis, Pharmacia & Upjohn and AstraZeneca. He hassupported clients across all healthcare sub-sectors including biotechnology,specialty pharmaceuticals, med-device, med-tech, diagnostics, and healthcareservices, and worked on a broad range of transactions with companies at allstages of development. Julian has also led companies in the healthcare space inthe US and the UK, including Britesmile, Inc. and Bioscience Managers (abiotechnology venture capital and corporate finance boutique).

Dr. Feneley is a qualified medical doctor from Guy's Hospital in London, andhas worked extensively in both Europe and the US. He has an M.B.B.S.,Bachelors of Medicine, Bachelors of Surgery and Honours degree in Medicine andPhysiology from London University.

Adrian Haxby added: "Julian's medical background and entrepreneurial approachmake him an excellent addition to Canaccord Genuity's Investment Banking team."

Julian's appointment follows the recruitment of Daniel Sharp and Dr. MatthijsSmith to the firm's Life Sciences team in Melbourne in October 2012, andHarrison Wehner as Managing Director covering healthcare in Boston, who joinedin November 2012 from Citigroup.

Canaccord Genuity is the global full service investment banking division ofCanaccord Financial Inc. (TSX: CF, LSE: CF.), offering institutional andcorporate clients idea-driven investment banking, merger and acquisition,research, sales and trading services from offices in 12 countries worldwide.Our team of nearly 1,000 capital markets and advisory professionals hasindustry and transactional expertise in 18 key sectors of the global economy.We are committed to providing valued services to our clients throughout theentire lifecycle of their business and operating as a gold standard independentinvestment bank - expansive in resources and reach, but targeted in industryexpertise, market focus and individual client attention.

More information is available at: www.canaccordgenuity.com

ABOUT CANACCORD FINANCIAL INC.:

Through its principal subsidiaries, Canaccord Financial Inc. is a leadingindependent, full-service financial services firm, with operations in twoprincipal segments of the securities industry: wealth management and globalcapital markets. Since its establishment in 1950, Canaccord has been driven byan unwavering commitment to building lasting client relationships. We achievethis by generating value for our individual, institutional and corporateclients through comprehensive investment solutions, brokerage services andinvestment banking services. Canaccord has offices in 13 countries worldwide,including Wealth Management offices located in Canada, Australia, the UK andEurope. Canaccord Genuity, the international capital markets division,operates in Canada, the US, the UK, France, Germany, Ireland, Italy, Hong Kong,mainland China, Singapore, Australia and Barbados.

Canaccord Financial Inc. is publicly traded under the symbol CF on the TSX andthe symbol CF. on the London Stock Exchange.

FOR FURTHER INFORMATION CONTACT:

Phone: +44 (0) 207 466 5000, email: [email protected]

Executive Vice President, Global Head of Corporate Development and Strategy

Phone: 416-869-3875, email: [email protected]

For investor relations inquiries contact:

Jamie Kokoska

Vice President, Investor Relations & Communications

Phone: 416-869-3891, email: [email protected]